Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer-Reference-Cited by-同舟云学术

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer

Published:2013-08-12 Issue:8 Volume:14 Page:703-710
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Al-Marrawi Mhd Yaser,Saroya Bikramajit Singh,Brennan Matthew C,Yang Zhaohai,Dykes Thomas M,El-Deiry Wafik S

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.4161/cbt.25191

Reference29 articles.

1. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

3. Blocking Oncogenic Ras Signaling for Cancer Therapy

4. Mutations of the BRAF gene in human cancer

5. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib;Cell Reports Medicine;2024-08

2. A novel cancer-associated fibroblasts risk score model predict survival and immunotherapy in lung adenocarcinoma;Molecular Genetics and Genomics;2024-07-17

3. Remodeling of sorafenib as an orally bioavailable ferroptosis inducer for Lung Cancer by chemical modification of adenine-binding motif;Biomedicine & Pharmacotherapy;2024-07

4. Translational research of new developments in targeted therapy of colorectal cancer;Pathology - Research and Practice;2023-12

5. Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer;Anticancer Research;2021-09